Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An immune-related prognostic model predicts neoplasm-immunity interactions for metastatic nasopharyngeal carcinoma. | Front Immunol | 2023 | 37063853 | PubTator, text mining | PubMed |
| Advances in the multi-omics landscape of follicular lymphoma. | Int J Biol Sci | 2023 | 37063433 | PubTator, text mining | PubMed |
| Epigenetically regulated gene expression profiles decipher four molecular subtypes with prognostic and therapeutic implications in gastric cancer. | Clin Epigenetics | 2023 | 37061743 | PubTator, text mining | PubMed |
| Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma. | Blood Adv | 2023 | 37058474 | PubTator, text mining | PubMed |
| Plasma-derived immune-related factors as biomarkers of osimertinib resistance in EGFR-mutant non-small cell lung cancer patients. | Transl Lung Cancer Res | 2023 | 37057104 | PubTator, text mining | PubMed |
| Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas. | Theranostics | 2023 | 37056564 | PubTator, text mining | PubMed |
| Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy. | Sci Rep | 2023 | 37055418 | PubTator, text mining | PubMed |
| Tumor-Infiltrating B Lymphocytes: Promising Immunotherapeutic Targets for Primary Liver Cancer Treatment. | Cancers (Basel) | 2023 | 37046842 | PubTator, text mining | PubMed |
| Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). | Cancers (Basel) | 2023 | 37046777 | PubTator, text mining | PubMed |
| Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors. | Cancers (Basel) | 2023 | 37046702 | PubTator, text mining | PubMed |
| The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens. | Cancers (Basel) | 2023 | 37046685 | PubTator, text mining | PubMed |
| Emerging Targeted Therapies for HER2-Positive Breast Cancer. | Cancers (Basel) | 2023 | 37046648 | PubTator, text mining | PubMed |
| iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. | Stem Cell Res Ther | 2023 | 37038186 | PubTator, text mining | PubMed |
| Cellular and molecular biomarkers of long COVID: a scoping review. | EBioMedicine | 2023 | 37037165 | PubTator, text mining | PubMed |
| The emerging role of noncoding RNAs in systemic lupus erythematosus: new insights into the master regulators of disease pathogenesis. | Ther Adv Chronic Dis | 2023 | 37035097 | PubTator, text mining | PubMed |
| Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach. | Front Immunol | 2023 | 37033944 | PubTator, text mining | PubMed |
| Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma. | Transl Androl Urol | 2023 | 37032757 | PubTator, text mining | PubMed |
| Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. | Signal Transduct Target Ther | 2023 | 37032379 | PubTator, text mining | PubMed |
| A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. | Leukemia | 2023 | 37031299 | PubTator, text mining | PubMed |
| The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. | Front Immunol | 2023 | 37025994 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=39